頁籤選單縮合
| 題 名 | 「建構中醫特色與智慧醫療模式計畫」--分項計畫3:發展中醫大數據資料分析及應用模式計畫--以過度肥胖為例=Application of Traditional Chinese Medicine (TCM) Big Data Analysis--Study about Obesity |
|---|---|
| 作 者 | 陳星諭; | 書刊名 | 中醫藥年報 |
| 卷 期 | 14 2025.12[民114.12] |
| 頁 次 | 頁(6)1-(6)94 |
| 分類號 | 413.2 |
| 關鍵詞 | 中醫; 中醫藥; 大數據; 肥胖; 真實世界數據; Big data analysis; Traditional Chinese medicine; Chinese herbal medicine; Obesity; Real-world data; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 大數據分析為一臨床資料處理與分析之重要工具,可作為常規臨床試驗之重 要參考與臨床經驗之重要依據,可用於處理重要臨床問題。依據 2013-2016 年「國 民營養狀況變遷調查」,我國 19 歲以上成人,過重及肥胖(BMI≧24)盛行率為 45.4%。肥胖和高血壓、糖尿病、高血脂和心血管疾病的形成有著密切的關係, 顯然肥胖的防治已經成為國際間重要的健康問題。現今西藥雖然有著明確的減重 效果,但仍有其侷限。在台灣,有一定比例的民眾透過服用中藥或接受針刺治療 控制體重,然而對於中醫治療的實際減重成效、可能風險和副作用,以及停止治 療後是否出現復胖情形並不清楚,找尋安全有效的中醫治療肥胖模式是本研究所 關心的議題。本研究之目的將以長庚醫院資料庫之臨床資料進行數據分析與比 較,以了解中草藥在減重之角色。 研究方法:收集 2014-2020 年,於長庚醫院門診肥胖患者的病歷資料,包括 病患門診的就診日期、年齡、性別、身高、體重、血壓、心率、診斷碼(包含門 診、急診、住院)、開立中藥複方及單方藥物、雷射針灸、西藥、處置、檢驗項 目、檢查項目及病歷記載的主觀與客觀描述。依據以上資料,預計分析 10000 筆就診紀錄,體重和 BMI 變化,以及中藥複方及單方藥物之種類、劑量、頻率、 使用時間、雷射針灸處置次數,並分析是否同時使用西藥以及肥胖相關的檢驗數 據 , 包 括 Sugar, HbA1c, Insulin level, HOMA-IR, Triglyceride, Total cholesterol, LDL, HDL, BUN, Cr., e-GFR, Na, K, AST, ALT, Albumin, Troponin, CKMB 項目。以開始使用中醫藥治療之日期為研究起始點 (index date),對照無 使用中醫藥之患者族群,進行前瞻性體重變化與副作用之分析。本研究之 Primary outcome 為治療後半年內之體重變化,而 Secondary outcome 為半年內 血 清 中 Sugar, HbA1c, Insulin level, HOMA-IR, Triglyceride, Total cholesterol, LDL, HDL 等指標之變化,此外,可能之副作用亦在評估範圍,例 如:肝腎功能損傷、心腦血管相關副作用,亦為分析重點。 此外,並定期召集包含巨量中心研究員之專家會議,並召開成果分享會以推 廣大數據分析,並針對大數據參與之臨床實踐、驗證之模式進行政策建議。 |
| 英文摘要 | Big data analysis is an important technique to analyze huge amount of clinical database and find out precious information about important health issue for clinical practice. According to “2013-2016 Nutrition and Health Survey in Taiwan”, the prevalence of overweight and obesity (BMI≧24) in people above 19 year-old is 45.4%。Obesity is correlated with the formation of hypertension, diabetes mellitus, hyperlipidemia and other cardiovascular disease. Thus, obesity prevention has become an important health issue worldwide.Although some drugs were proven to have weight lose effect, there are several adverse effects and risks while taking these drugs. For example, Sibutramine increased the risk of cardiovascular disease and was withdrawn from market in 2010. Orlistat decreases the absorption of fat-soluble vitamins, causes gastrointestinal symptoms and has potential hepatotoxicity. Lorcaserin may induce headache, nausea and potentially lower blood sugar. In Taiwan, there are many people receiving traditional Chinese medicine (TCM) or acupuncture to help control body weight. However, little information about the efficacy of traditional Chinese medicine on weight control, potential risks and adverse effects is known. The aim of our study is to find out a safe and efficient treatment model of traditional Chinese medicine on weight control. In this project, we will try to utilize the information in the CGRD to explore the usefulness of Chinese herbal medicine (CHM) in managing obesity. The diagnosis code of obesity and BMI > 24 would be used to collect obesity patients in the CGRD during 2014-2020. The accessible clinical information would be collected, such as visit date, age, gender, height, weight, blood pressure, heart beat, diagnostic codes, Chinese medicine prescriptions, the frequency of laser acupuncture treatment, western medicine in combination, laboratory data, examinations and liver echo reports. The primary outcome will be the body weight change in half year after traditional Chinese medicine and/or laser acupuncture treatment. The secondary outcome will be the changes of serum biochemistry data, such as sugar, HbA1c, Insulin level, HOMA-IR, Triglyceride, Total cholesterol, LDL, HDL, in half year after traditional Chinese medicine and/or laser acupuncture treatment. Besides, we’ll also evaluate whether there are potential adverse effects, such as renal/liver function and cardiovascular system impairment, or not. |
本系統中英文摘要資訊取自各篇刊載內容。